A Phase 2 interventional study of Deucrictibant and Placebo in Hereditary Angioedema, Hereditary Angioedema Type I and Hereditary Angioedema Type II, sponsored by Pharvaris Netherlands B.V.. Completed at 36 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Pharvaris Netherlands B.V. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 35th largest by enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2021, is one of 16 in phase 2, and was the 47th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
Ionis Pharmaceuticals, Inc. · Sites in United States, Australia, Italy and 2 more countries
Ages 2–11
ADARx Pharmaceuticals, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Pharvaris Netherlands B.V. · Sites in United States, Australia, Austria and 13 more countries
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 42 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 57 across the 74 interventional studies, 168 across the 7 observational. Of the 62 that completed or were terminated, 47 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 84 have an industry lead sponsor. The 10 most frequent:
Pharvaris Netherlands B.V. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Pharvaris Netherlands B.V. has 8 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
7 of the studies in Angioedemas, Hereditary with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.
In Part I of the study, patients in non-attack state receive the assigned active single dose of deucrictibant at the study center to assess pharmacokinetics (the way the body absorbs, distributes, and gets rid of the drug) and safety. In Part II of the study, patients self-administer blinded study drug at home to treat three HAE attacks with deucrictibant or placebo (cross-over).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single low dose of deucrictibant or placebo
Drug: Deucrictibant · Drug: Placebo
Single medium dose of deucrictibant or placebo
Drug: Deucrictibant · Drug: Placebo
Single high dose of deucrictibant or placebo
Drug: Deucrictibant · Drug: Placebo
deucrictibant soft capsules for oral use
Also known as: PHA-022121, PHA121, PHVS416
Matching placebo capsules for oral use
Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment
The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)
Time frame: Assessed from pre-treatment to 4 hours post-treatment
Time to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score
VAS-3 scores range between 0 and 100.
Time frame: Assessed from pre-treatment to 48-hours post-treatment
Time to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3)
VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value \< 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.
Time frame: Assessed from pre-treatment to 48 hours post-treatment
Time to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score
Time to a ≥50% reduction in VAS-3 composite score from the pre-treatment score.
Time frame: Assessed from pre-treatment to 48 hours post-treatment
Change in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment
MSCS scores range between 0 and 3. A higher score means a worse outcome.
Time frame: Pre-treatment and 4 hours post-treatment
Treatment Outcome Score (TOS) at 4 Hours Post-treatment
TOS range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.
Time frame: 4 hours post-treatment
Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom
Time to onset of primary symptom relief assessed by a 30% reduction in the VAS for the primary symptom within 48 hours post-treatment
Time frame: Within 48 hours post-treatment
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours.
Proportion of blinded study drug treated attacks requiring HAE rescue medication within 12 hours post-treatment.
Time frame: Assessed at 12 hours post study drug treatment
Time to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatment
The proportion of treated attacks with first use of HAE rescue medication within 48 hours post-treatment with PHA-022121.
Time frame: Assessed at 48 hours post study drug treatment
Time to Change in the VAS Score for Skin Pain Score - 30% Reduction
Time to change in the VAS score for Skin Pain Score - 30% reduction within 48-hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Within 48 hours post treatment
Change in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment
Change in the Mean Symptom Complex Severity (MSCS) score from pre-treatment to 24 hours post-treatment. A lower MSCS score indicates a better outcome.
Time frame: 24 hours post-treatment
TOS at 24 Hours Post-treatment
Treatment outcome score at 24 hours post-treatment. A higher score indicates improvement.
Time frame: Assessed within 24 hours post treatment
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
Time frame: 48 hours post-treatment
Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score
Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Within 48 hours post-treatment
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 24 Hours.
Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.
Time frame: Assessed at 24 hours post-study drug treatment
Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 48 Hours
Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.
Time frame: Assessed at 48 hours post-study drug treatment
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
Time frame: 48 hours post-treatment
Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
Time frame: 48 hours post-treatment
Time to Change in the VAS Score for Skin Swelling Score - 30% Reduction
Time to change in the VAS score for Skin Swelling Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Within 48 hours post-treatment
Time to Change in the VAS Score for Abdominal Pain Score - 30% Reduction
Time to change in the VAS score for Abdominal Pain Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
Time frame: Within 48 hours post-treatment
A total of 89 patients were screened, of which 74 patients were enrolled and randomized to the 3 PHA-022121 cohorts as follows: 25 participants to the 30 mg cohort, 25 participants to the 20 mg cohort, and 24 participants to the 10 mg cohort. From Part I to Part II, participants remained at their randomly assigned dose level. The majority of screen failures were due to inclusion criterion not met.
| Milestone | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg |
|---|---|---|---|
| Started | 24 | 25 | 25 |
| Completed | 24 | 24 | 25 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Milestone | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg |
|---|---|---|---|
| Started | 24 | 24 | 25 |
| Attack 1 - pha-022121 | 16 | 13 | 17 |
| Attack 1 - placebo | 6 | 6 | 6 |
| Attack 2 - pha-022121 | 12 | 8 | 12 |
| Attack 2 - placebo | 7 | 8 | 7 |
| Attack 3 - pha-022121 | 11 | 10 | 10 |
| Attack 3 - placebo | 7 | 3 | 6 |
| Completed | 16 | 12 | 12 |
| Not completed | 8 | 12 | 13 |
| Withdrew: Withdrawal by subject | 2 | 3 | 5 |
| Withdrew: Participants met primary analysis criteria | 6 | 9 | 8 |
The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment | -14.83 ± 1.833 | -13.10 ± 2.111 | -14.37 ± 1.975 | 1.92 ± 1.596 |
VAS-3 scores range between 0 and 100.
| Hours | PHA-022121 Low Dose -10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Onset of Symptom Relief by ≥30% Reduction in Visual Analogue Scale (VAS-3) Composite Score From the Pre-treatment Score | 2.1 (1.5 to 2.9) | 2.7 (1.9 to 3.5) | 2.5 (1.9 to 3.8) | 8.0 (7.6 to 48.0) |
VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value \< 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Onset of Almost Complete or Complete Symptom Relief by Visual Analogue Scale (VAS-3) | 5.8 (3.6 to 7.5) | 20.0 (4.5 to 20.0) | 20.0 (6.0 to 20.1) | 42.0 (22.0 to 48.0) |
Time to a ≥50% reduction in VAS-3 composite score from the pre-treatment score.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to a ≥50% Reduction in VAS-3 Composite Score From the Pre-treatment Score | 3.3 (2.4 to 3.9) | 4.0 (2.9 to 6.0) | 4.0 (3.3 to 5.8) | 22.8 (20.0 to 24.1) |
MSCS scores range between 0 and 3. A higher score means a worse outcome.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Change in the Mean Symptom Complex Severity (MSCS) Score From Pre-treatment to 4 Hours Post-treatment | -1.08 (-1.33 to -0.83) | -0.91 (-1.19 to -0.62) | -0.68 (-0.95 to -0.40) | -0.29 (-0.51 to -0.08) |
TOS range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Treatment Outcome Score (TOS) at 4 Hours Post-treatment | 60.52 (41.74 to 79.29) | 59.08 (37.58 to 80.57) | 67.44 (47.15 to 87.74) | -3.62 (-19.68 to 12.45) |
Time to onset of primary symptom relief assessed by a 30% reduction in the VAS for the primary symptom within 48 hours post-treatment
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom | 2.0 (1.4 to 2.4) | 3.0 (1.9 to 4.1) | 2.9 (1.9 to 3.9) | 23.3 (6.1 to NA) |
Proportion of blinded study drug treated attacks requiring HAE rescue medication within 12 hours post-treatment.
| Attacks requiring HAE rescue medication | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Proportion of Study Drug Treated Attacks Requiring HAE Rescue Medication Within 12 Hours. | 7 | 3 | 2 | 31 |
The proportion of treated attacks with first use of HAE rescue medication within 48 hours post-treatment with PHA-022121.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to First HAE Rescue Medication Use for Study Drug-treated Attacks Within 48 Hours Post-treatment | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 6.0 (4.4 to 13.1) |
Time to change in the VAS score for Skin Pain Score - 30% reduction within 48-hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Change in the VAS Score for Skin Pain Score - 30% Reduction | 2.9 (1.9 to 5.7) | 3.4 (1.9 to 6.0) | 2.7 (1.9 to 3.9) | 22.8 (8.7 to NA) |
Change in the Mean Symptom Complex Severity (MSCS) score from pre-treatment to 24 hours post-treatment. A lower MSCS score indicates a better outcome.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Change in Mean Symptom Complex Severity Score From Pre-treatment to 24 Hours Post-treatment | -1.65 ± 0.117 | -1.50 ± 0.123 | -1.68 ± 0.122 | -1.20 ± 0.163 |
Treatment outcome score at 24 hours post-treatment. A higher score indicates improvement.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| TOS at 24 Hours Post-treatment | 94.44 ± 21.183 | 93.60 ± 21.190 | 94.44 ± 16.013 | 76.92 ± 38.813 |
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Effectiveness Domain Score | 79.17 ± 23.179 | 70.45 ± 30.290 | 72.92 ± 23.085 | 65.38 ± 23.532 |
Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Onset of Primary Symptom Relief by 50% Reduction in VAS Score | 2.9 (2.4 to 3.9) | 4.5 (2.9 to 8.5) | 4.0 (2.5 to 5.8) | 22.8 (5.8 to 24.1) |
Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.
| Attacks requiring HAE rescue medication | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Number of treated attacks | 37 | 28 | 31 | 51 |
| Number of treated attacks requiring HAE rescue medication | 9 | 3 | 4 | 37 |
Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 hours has been experienced.
| Attacks requiring HAE rescue medication | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Number of treated attacks | 37 | 28 | 31 | 51 |
| Number of treated attacks requiring HAE rescue medication | 9 | 4 | 5 | 37 |
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Convenience Domain Score | 80.56 ± 16.569 | 83.08 ± 23.096 | 77.55 ± 20.229 | 76.07 ± 27.441 |
MMRM analysis of Treatment Satisfaction Questionnaire for Medication (TSQM) at 48 hours post-treatment. The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.
| Score on a scale | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment - Satisfaction Domain Score | 82.50 ± 18.907 | 80.68 ± 29.702 | 76.74 ± 22.113 | 64.10 ± 24.623 |
Time to change in the VAS score for Skin Swelling Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Change in the VAS Score for Skin Swelling Score - 30% Reduction | 2.5 (1.4 to 5.8) | 3.5 (2.2 to 20.0) | 3.8 (1.9 to 4.8) | 23.3 (3.9 to NA) |
Time to change in the VAS score for Abdominal Pain Score - 30% reduction within 48 hours post-treatment. VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.
| Hours | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Placebo |
|---|---|---|---|---|
| Time to Change in the VAS Score for Abdominal Pain Score - 30% Reduction | 1.9 (1.1 to 2.1) | 1.4 (0.9 to 2.5) | 2.9 (1.9 to 7.5) | 20.0 (2.9 to NA) |
Collected over All AEs (including SAEs) recorded from the time of signing informed consent until the end-of-study visit. Timeframe for reporting adverse events: 5 days post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part I PHA-022121 Low Dose - 10 mg | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Part I PHA-022121 Medium Dose - 20 mg | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| Part I PHA-022121 High Dose - 30 mg | 0/25 (0%) | 0/25 (0%) | 4/25 (16%) |
| Part II PHA-022121 Low Dose - 10 mg Study Drug Treated Attacks | 0/38 (0%) | 0/38 (0%) | 3/38 (7.9%) |
| Part II PHA-022121 Medium Dose - 20 mg Study Drug Treated Attacks | 0/29 (0%) | 0/29 (0%) | 1/29 (3.4%) |
| Part II PHA-022121 High Dose - 30 mg Study Drug Treated Attacks | 0/36 (0%) | 0/36 (0%) | 2/36 (5.6%) |
| Part II PHA-022121 Low Dose - 10 mg Participants | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| Part II PHA-022121 Medium Dose - 20 mg Participants | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Part II PHA-022121 High Dose - 30 mg Participants | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Part II Placebo | 0/53 (0%) | 0/53 (0%) | 4/53 (7.5%) |
| Event | Part I PHA-022121 Low Dose - 10 mg | Part I PHA-022121 Medium Dose - 20 mg | Part I PHA-022121 High Dose - 30 mg | Part II PHA-022121 Low Dose - 10 mg Study Drug Treated Attacks | Part II PHA-022121 Medium Dose - 20 mg Study Drug Treated Attacks | Part II PHA-022121 High Dose - 30 mg Study Drug Treated Attacks | Part II PHA-022121 Low Dose - 10 mg Participants | Part II PHA-022121 Medium Dose - 20 mg Participants | Part II PHA-022121 High Dose - 30 mg Participants | Part II Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/23 | 1/24 | 2/25 | 0/38 | 0/29 | 0/36 | 0/21 | 0/16 | 0/22 | 0/53 |
| NasopharyngitisInfections and infestations | 0/23 | 0/24 | 2/25 | 1/38 | 0/29 | 0/36 | 1/21 | 0/16 | 0/22 | 0/53 |
| Lower urinary tract symptomsRenal and urinary disorders | 0/23 | 0/24 | 0/25 | 0/38 | 1/29 | 0/36 | 0/21 | 1/16 | 0/22 | 0/53 |
| FatigueGeneral disorders | 0/23 | 0/24 | 0/25 | 1/38 | 0/29 | 1/36 | 1/21 | 0/16 | 1/22 | 0/53 |
| Gastrointestinal infectionInfections and infestations | 0/23 | 0/24 | 0/25 | 1/38 | 0/29 | 0/36 | 1/21 | 0/16 | 0/22 | 0/53 |
| Blood bilirubin increasedInvestigations | 0/23 | 0/24 | 0/25 | 0/38 | 0/29 | 1/36 | 0/21 | 0/16 | 1/22 | 0/53 |
| NauseaGastrointestinal disorders | 1/23 | 0/24 | 0/25 | 0/38 | 0/29 | 1/36 | 0/21 | 0/16 | 1/22 | 0/53 |
| VomitingGastrointestinal disorders | 0/23 | 0/24 | 0/25 | 0/38 | 0/29 | 1/36 | 0/21 | 0/16 | 1/22 | 0/53 |
| Viral InfectionInfections and infestations | 1/23 | 0/24 | 0/25 | 0/38 | 0/29 | 0/36 | 0/21 | 0/16 | 0/22 | 0/53 |
| Dental cariesGastrointestinal disorders | 0/23 | 1/24 | 0/25 | 0/38 | 0/29 | 0/36 | 0/21 | 0/16 | 0/22 | 0/53 |
Full Analysis Set (FAS): The FAS was defined as all participants enrolled and randomized in the study. Participants were analyzed based on the intention-to-treat principle, i.e., according to their randomized treatment assignment regardless of actual treatment taken.
| Age, Continuous(years) | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Total |
|---|---|---|---|---|
| Mean | 42.9 ± 14.15 | 45.7 ± 13.89 | 41.4 ± 15.38 | 43.3 ± 14.41 |
| Age, Customized(Participants) | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 22 | 24 | 23 | 69 |
| From 65-84 years | 2 | 1 | 2 | 5 |
| Sex: Female, Male(Participants) | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Total |
|---|---|---|---|---|
| Female | 17 | 17 | 15 | 49 |
| Male | 7 | 8 | 10 | 25 |
| Race/Ethnicity, Customized(Participants) | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Total |
|---|---|---|---|---|
| White | 22 | 24 | 25 | 71 |
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| Other | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | PHA-022121 Low Dose - 10 mg | PHA-022121 Medium Dose - 20 mg | PHA-022121 High Dose - 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 0 | 5 |
| Not Hispanic or Latino | 18 | 22 | 24 | 64 |
| Not Reported | 3 | 1 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Sep 2022, 19 months.
Results were first posted in Dec 2025, 3 years 2 months after primary completion. A results delay was requested in Jun 2023.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pharvaris Netherlands B.V.